therapy improves cognition, mood, and function of brain tumor patients
Meyers CA, Weitzner MA, Valentine AD, Levin VA
Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Houston
77030, USA. email@example.com
Purpose. Patients with malignant glioma develop progressive
neurobehavioral deficits over the course of their illness.
These are caused both by the effects of the disease and the effects of radiation
We sought to determine whether methylphenidate treatment would improve these
patients' neurobehavioral functioning despite their expected neurologic
and Methods. Thirty patients with primary brain tumors underwent neuropsychologic assessment
before and during treatment with methylphenidate.
Ability to function in activities of daily living and magnetic resonance imaging
(MRI) findings were also documented.
Patients were assessed on 10, 20, and 30 mg of methylphenidate twice
Significant improvements in cognitive function were observed on the 10-mg
Functional improvements included improved gait, increased stamina and motivation
to perform activities, and in one case, increased bladder control.
Adverse effects were minimal and immediately resolved when treatment was
There was no increase in seizure frequency and the majority of patients on
glucocorticoid therapy were able to decrease their dose.
Gains in cognitive function and ability to perform activities were observed in
the setting of progressive neurologic injury documented by MRI in half of the
This study demonstrated improved patient function in the setting of a
progressive neurologic illness.
Methylphenidate should be more widely considered as adjuvant brain tumor
9667273 [PubMed - indexed for MEDLINE]